Rezlod (dorzolamide) eye drops solution 2% 5 ml. bottle dropper

Description

Rezlod (dorzolamide) eye drops solution 2% 5 ml. bottle dropper

Composition

active substance: dorzolamide;

1 ml of solution contains 20 mg of dorzolamide (as dorzolamide hydrochloride);

excipients: mannitol (E 421), benzalkonium chloride, hydroxyethyl cellulose, sodium citrate, sodium hydroxide, water for injections.

Medicinal form

Eye drops, solution.

Main physicochemical properties: transparent, slightly viscous, colorless aqueous solution.

Pharmacotherapeutic group

Antiglaucoma drugs and miotic agents. Carbonic anhydrase inhibitors. Dorzolamide.
ATX code S01E C03.

Pharmacological properties

Rezlod contains dorzolamide hydrochloride, a strong human carbonic anhydrase II (CA-II) inhibitor. After topical ophthalmic application, dorzolamide reduces elevated intraocular pressure, associated or not associated with glaucoma, which is a major risk factor in the pathogenesis of optic nerve damage and narrowing of the visual field. Dorzolamide does not cause constriction of the pupil and reduces intraocular pressure without developing such side effects as night blindness and accommodation spasm. Dorzolamide has little or no effect on heart rate or blood pressure.

Since the mechanism of action of dorzolamide differs from the mechanism of action of beta-adrenoceptor blockers, when it is used in such a combination as concomitant therapy, a synergistic effect of both components is observed, which is accompanied by an additional decrease in intraocular pressure.

Indications 

It is used as a medicine that is used in the treatment of:

• increased intraocular pressure;
• open-angle glaucoma;
• pseudoexfoliative glaucoma;
• other types of secondary open-angle glaucoma.

The main active ingredient of the drug – dorzolamide – has shown its effectiveness both in monotherapy and when used in combination with local beta-blockers. Dorzolamide reduced intraocular pressure throughout the day, and this effect persisted for a significant time.
In terms of its effectiveness, this drug (after long-term monotherapy) showed its similarity with betaxolol and only to some extent lower than timolol.

Contraindications

Not applicable if the patient has hypersensitivity (allergy) to one of the components that make up the drug.
In addition, the use of this drug is contraindicated if the patient has:

• severe renal dysfunction;
• hyperchloremic acidosis;
• allergy to sulfa drugs.

Simultaneous use with drugs that inhibit the production of an aqueous liquid after filtration measures is not recommended, since this can cause detachment of the choroid.
It is not used in pediatrics.

Application during pregnancy and lactation

This drug is not recommended for use during pregnancy.
If there is a need to use this drug during breastfeeding, then it is better to suspend lactation for this period.

Method of administration and dosage

The drug Rezlod is used 1 drop in each affected eye (in the conjunctival sac), three times a day.
With combined or additional therapy, 1 drop is administered twice a day.
In order for the drug to be better absorbed, immediately after instillation, close your eyes, lightly press your eyelids and hold it for a few seconds.
If there is a need to replace another local antiglaucoma drug with dorzolamide, you should suspend treatment with this drug and start using this drug the next day.
If there is a need to use several topical ophthalmic agents, they should be administered with an interval of 10 minutes.
Before introducing the drug into the eye, wash your hands thoroughly and avoid contact of the dropper tip with the eye or skin during instillation.
If these precautions are violated, the drug can be contaminated with foreign bacteria, and the infection can subsequently get into the eyes, which can have dire consequences.

Overdose

Overdose with this drug was observed extremely rarely. In rare cases, overdose has been observed:

• drowsiness (with accidental oral ingestion);
• nausea, dizziness, headache;
• feeling tired;
• atypical dreams;
• dysphagia.

Disorders of the central nervous system, manifestations of asthenia, electrolyte disturbances are also possible.
Symptomatic treatment is recommended. It is necessary to control the content of electrolytes, in particular potassium, in blood plasma, monitor blood pH.

Side effects

Adverse reactions have been observed with this drug:

• headache, paresthesia, dizziness;
• burning and tingling in the eyes when the drug is injected;
• external punctate keratitis, lacrimation, blepharitis, conjunctivitis;
• itchy eyes, irritation of the mucous membranes of the eyes, blurred vision, iridocyclitis;
• clumping of the eyelids, rapidly passing hyperopia;
• nosebleeds, nausea, bitterness in the mouth, sore throat;
• contact dermatitis, toxic epidermal necrolysis;
• urolithiasis disease;
• asthenia, fatigue;
• hives, itching, rash, shortness of breath;
• angioneurotic edema, bronchospasm.

If any unusual side effects occur as a result of taking this drug, you should consult your doctor about possible changes in the treatment regimen.